A Phase 1, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of oral ETX0282 Administered in Healthy Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Cefpodoxime/ETX 0282 (Primary) ; Cefpodoxime proxetil
- Indications Enterobacteriaceae infections; Gram-negative infections; Urinary tract infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Entasis Therapeutics
- 05 Sep 2019 Planned number of patients changed from 144 to 112.
- 05 Sep 2019 Planned End Date changed from 1 Jul 2019 to 1 Sep 2019.
- 05 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History